CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $9.67B, above the global median of $1.18B
- PositionOperating margin is 74.4%, higher than 95% of its Biotechnology peers (median -24.1%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
9.67BUSDvs all stocks (USD)
Trailing P/E
147.09xvs Biotechnology peers
Revenue (TTM)
281.99MUSDvs all stocks (USD)
Profit Margin
29.40%vs Biotechnology peers
Beta
1.79xvs all stocks
52-Week Change
153.18%vs all stocks
Market Capitalization
9.67BUSDvs all stocks (USD)
Enterprise Value
9.03BUSDvs all stocks (USD)
Trailing P/E
147.09xvs Biotechnology peers
PEG Ratio
-0.2679xvs Biotechnology peers
Price to Sales (TTM)
34.76xvs Biotechnology peers
Price to Book (MRQ)
11.64xvs Biotechnology peers
Enterprise to Revenue
32.02xvs Biotechnology peers
Enterprise to EBITDA
150.79xvs Biotechnology peers
Profit Margin
29.40%vs Biotechnology peers
Operating Margin
74.37%vs Biotechnology peers
Return on Assets (TTM)
4.55%vs Biotechnology peers
Return on Equity (TTM)
10.98%vs Biotechnology peers
Revenue (TTM)
281.99MUSDvs all stocks (USD)
Revenue per Share (TTM)
4.36USDUpdated Aug 28, 2026Quarterly Revenue Growth
3749.20%vs Biotechnology peers
Gross Profit (TTM)
281.99MUSDvs all stocks (USD)
EBITDA (TTM)
59.88MUSDvs all stocks (USD)
Net Income (TTM)
82.91MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
3749.17%vs Biotechnology peers
Operating Cash Flow (TTM)
131.20MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
96.15MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Aug 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
46.02MUSDFY2025 · Dec 31, 2025Operating Income
-158.13MUSDvs all stocks (USD)
Pre-tax Income
-129.31MUSDFY2025 · Dec 31, 2025Income Tax Expense
838.00KUSDFY2025 · Dec 31, 2025Net Income
-130.15MUSDFY2025 · Dec 31, 2025EBIT
-158.13MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-156.85MUSDFY2025 · Dec 31, 2025Research & Development
159.29MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
44.85MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
28.79MUSDFY2025 · Dec 31, 2025EPS (Basic)
-2.05USDFY2025 · Dec 31, 2025EPS (Diluted)
-2.05USDFY2025 · Dec 31, 2025Basic Shares Outstanding
63.57MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
63.57MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-130.15MUSDFY2025 · Dec 31, 2025Operating Cash Flow
65.37MUSDFY2025 · Dec 31, 2025Free Cash Flow
63.78MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
128.68MUSDFY2025 · Dec 31, 2025Interest Paid
3.69MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-130.15MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.28MUSDFY2025 · Dec 31, 2025Stock-based Compensation
45.97MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.58MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
164.88MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
3.72MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-21.92MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.59MUSDFY2025 · Dec 31, 2025Purchase of Investments
-546.59MUSDFY2025 · Dec 31, 2025Sale of Investments
498.84MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-49.33MUSDFY2025 · Dec 31, 2025Other Financing Charges
-479.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-479.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
64.67MSharesUpdated Aug 28, 2026Float Shares
52.89MSharesUpdated Aug 28, 2026Shares Short
7.79MSharesUpdated Aug 28, 2026Short Ratio
14.77daysvs all stocks
Short % of Shares Outstanding
13.99%vs all stocks
% Held by Insiders
0.71%vs all stocks
% Held by Institutions
119.79%vs all stocks
Total Cash (MRQ)
782.58MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
12.09USDUpdated Aug 28, 2026Total Debt (MRQ)
9.22MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0109xvs Biotechnology peers
Current Ratio (MRQ)
21.71xvs Biotechnology peers
Book Value per Share (MRQ)
13.01USDUpdated Aug 28, 2026Total Assets
668.19MUSDvs all stocks (USD)
Total Current Assets
577.57MUSDFY2025 · Dec 31, 2025Total Liabilities
53.48MUSDFY2025 · Dec 31, 2025Total Non-current Assets
90.61MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
8.04MUSDFY2025 · Dec 31, 2025Total Current Liabilities
45.44MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
128.39MUSDFY2025 · Dec 31, 2025Other Short-term Investments
438.97MUSDFY2025 · Dec 31, 2025Accounts Payable
5.34MUSDFY2025 · Dec 31, 2025Short-term Debt
2.28MUSDFY2025 · Dec 31, 2025Deferred Revenue
9.55MUSDFY2025 · Dec 31, 2025Long-term Debt
8.04MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-470.67MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
614.71MUSDvs all stocks (USD)
52-Week Low
54.50USDUpdated Aug 28, 202652-Week High
160.81USDUpdated Aug 28, 202652-Week Change
153.18%vs all stocks
Beta
1.79xvs all stocks
50-Day MA
136.70USDUpdated Aug 28, 2026200-Day MA
103.85USDUpdated Aug 28, 2026Avg 10-Day Volume
504.00KSharesUpdated Aug 28, 2026Avg 30-Day Volume
514.27KSharesUpdated Aug 28, 2026Diluted EPS (TTM)
1.03USDUpdated Aug 28, 2026Other Income / Expense
27.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 74.4%, higher than 95% of its Biotechnology peers (median -24.1%)Significant
Operating margin: 0.74Industry median: -0.24Industry P95: 0.38Peers compared: 194
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $9.67B, above the global median of $1.18BNotable
Market cap (USD): 9,673,888,607Global Median: 1,179,398,897.704
Levered free cash flow is $96.15M, above the global median of $19.19MNotable
Levered free cash flow (USD): 96,145,752Global Median: 19,189,974.917
Companies that share the same coordination system — how they create, deliver, or capture value.
Asymchem Laboratories (Tianjin) Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Nuvalent, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Fosun Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kymera Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Masimo Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Insulet Corporation
Tier 1ProductionApproval-Gated PipelineRule
Aurobindo Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Laurus Labs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Abivax SA
Tier 1ProductionApproval-Gated PipelineRule
Apogee Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Abeona Therapeutics Inc.
2 interpretationsCash-Flow Ratios ElevatedHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
ASTERA LABS INC COMMON STOCK (Ticker: 1ALAB)
2 interpretationsCash-Flow Ratios ElevatedHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Kneat.com Inc.
2 interpretationsCash-Flow Ratios ElevatedHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC